Integrin-IN-2 (compound 39) is an orally bioavailable pan αv integrin inhibitor. Integrin-IN-2 can increases the αvβ6, αvβ3, αvβ5 and αvβ8 binding affinities with pIC 50 values of 7.8, 8.4, 8.4 and 7.4, respectively [1].
In Vivo, In vivo pharmacokinetic studies in CD rats revealed that racemic Integrin-IN-2 (compound 39) has a low plasma clearance of 8 mL/(min kg), a low to moderate volume of distribution of 0.5 L/kg, a moderate halflife of 1.8 h, and very high bioavailability of 98%[1].
References:
[1]. Anderson NA, et al. Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis. J Med Chem. 2019 Oct 10;62(19):8796-8808.
In Vivo, In vivo pharmacokinetic studies in CD rats revealed that racemic Integrin-IN-2 (compound 39) has a low plasma clearance of 8 mL/(min kg), a low to moderate volume of distribution of 0.5 L/kg, a moderate halflife of 1.8 h, and very high bioavailability of 98%[1].
References:
[1]. Anderson NA, et al. Discovery of an Orally Bioavailable Pan αv Integrin Inhibitor for Idiopathic Pulmonary Fibrosis. J Med Chem. 2019 Oct 10;62(19):8796-8808.